Observation on the clinical efficacy of montelukast and azithromycin combined with methylprednisolone in the treatment of Mycoplasma pneumoniae pneumonia in children
Objective:To analyze the clinical efficacy of montelukast combined with azithromycin and methylprednisolone in the treatment of Mycoplasma pneumoniae pneumonia in children.Methods:Sixty-six children with Mycoplasma pneumoniae pneumonia admitted to our hospital from February 2022 to September 2023 were selected as the study subjects.They were randomly divided into a reference group(n=32)and a combination group(n=34)using the envelope method.The reference group was treated with montelukast and azithromycin,while the combination group was treated with methylprednisolone in addition to the reference group.The clinical efficacy,time of symptom disappearance,length of hospital stay,inflammation indicators before and after treatment,and incidence of adverse reactions were compared between the two groups.Results:The effective rate of the combination group(97.06%)was higher than that of the control group(81.25%)(P<0.05);Comparison of clinical indicators showed that the disappearance time of fever,asthma,cough,and wet rales,as well as the total length of hospital stay in the combination group,were shorter than those in the control group(P<0.05);Comparison of inflammatory indicators showed that the levels of serum procalcitonin(PCT),white blood cells(WBC),and neutrophils(NE)in the combination group were lower than those in the control group(P<0.05);There was no statistically significant difference in adverse reactions between the reference group and the combination group(P>0.05).Conclusion:The clinical efficacy of using montelukast and azithromycin combined with methylprednisolone in the treatment of children with Mycoplasma pneumoniae pneumonia is good.It can effectively alleviate clinical symptoms such as fever and cough,shorten hospitalization time,and improve inflammation levels,with good clinical value.
NETL
NSTL
万方数据
